PURPOSE: To investigate the role of IMRT in reducing the risk of acute genito-urinary (GU), upper gastrointestinal (uGI) and lower gastrointestinal (lGI) toxicity following whole-pelvis irradiation (WPRT) after radical prostatectomy. PATIENTS AND METHODS: 172 consecutive patients with prostate cancer were post-operatively irradiated to the prostatic bed (PB) and pelvic lymph-nodal area with adjuvant (n=100) or salvage (n=72) intent. Eighty-one patients underwent three-dimensional conformal (3DCRT) WPRT, while the remaining 91 underwent IMRT (54/91 with helical tomotherapy (HTT); 37/91 with Linac intensity-modulated RT (LinacIMRT)). RESULTS: Patients treated with IMRT experienced a decreased risk of acute toxicity. The crude incidence of grade > or =2 toxicity was GU 12.3% vs. 6.6% (p=0.19); lGI 8.6% vs. 3.2% (p=0.14); uGI 22.2% vs. 6.6% (p=0.004), for 3DCRT and IMRT, respectively. With respect to uGI and lGI, the acute toxicity profile of the HTT patients was even better when compared to that of 3DCRT patients (crude incidence:1.8% and 0.0%, respectively). Treatment interruptions due to uGI toxicity were 11/81 in the 3DCRT group vs. 2/91 in the IMRT group (p=0.006). CONCLUSIONS: The risk of acute toxicity following post-operative WPRT delivered by means of IMRT was reduced compared to that of 3DCRT. The most significant reduction concerned uGI, mainly owing to better bowel sparing with IMRT.
PURPOSE: To investigate the role of IMRT in reducing the risk of acute genito-urinary (GU), upper gastrointestinal (uGI) and lower gastrointestinal (lGI) toxicity following whole-pelvis irradiation (WPRT) after radical prostatectomy. PATIENTS AND METHODS: 172 consecutive patients with prostate cancer were post-operatively irradiated to the prostatic bed (PB) and pelvic lymph-nodal area with adjuvant (n=100) or salvage (n=72) intent. Eighty-one patients underwent three-dimensional conformal (3DCRT) WPRT, while the remaining 91 underwent IMRT (54/91 with helical tomotherapy (HTT); 37/91 with Linac intensity-modulated RT (LinacIMRT)). RESULTS:Patients treated with IMRT experienced a decreased risk of acute toxicity. The crude incidence of grade > or =2 toxicity was GU 12.3% vs. 6.6% (p=0.19); lGI 8.6% vs. 3.2% (p=0.14); uGI 22.2% vs. 6.6% (p=0.004), for 3DCRT and IMRT, respectively. With respect to uGI and lGI, the acute toxicity profile of the HTT patients was even better when compared to that of 3DCRT patients (crude incidence:1.8% and 0.0%, respectively). Treatment interruptions due to uGI toxicity were 11/81 in the 3DCRT group vs. 2/91 in the IMRT group (p=0.006). CONCLUSIONS: The risk of acute toxicity following post-operative WPRT delivered by means of IMRT was reduced compared to that of 3DCRT. The most significant reduction concerned uGI, mainly owing to better bowel sparing with IMRT.
Authors: Giuseppe Ferrera; Gianluca Mortellaro; Mariella Mannino; Giovanni Caminiti; Antonio Spera; Vanessa Figlia; Giuseppina Iacoviello; Gioacchino Di Paola; Rosario Mazzola; Antonio Lo Casto; Filippo Alongi; Maria Pia Pappalardo; Roberto Lagalla Journal: Radiol Med Date: 2015-05-24 Impact factor: 3.469
Authors: Deborah W Bruner; Daniel Hunt; Jeff M Michalski; Walter R Bosch; James M Galvin; Mahul Amin; Canhua Xiao; Jean-Paul Bahary; Malti Patel; Susan Chafe; George Rodrigues; Harold Lau; Marie Duclos; Madhava Baikadi; Snehal Deshmukh; Howard M Sandler Journal: Cancer Date: 2015-04-02 Impact factor: 6.860
Authors: Alan Dal Pra; Cedric Panje; Thomas Zilli; Winfried Arnold; Kathrin Brouwer; Helena Garcia; Markus Glatzer; Silvia Gomez; Fernanda Herrera; Khanfir Kaouthar; Alexandros Papachristofilou; Gianfranco Pesce; Christiane Reuter; Hansjörg Vees; Daniel Rudolf Zwahlen; Daniel Engeler; Paul Martin Putora Journal: Strahlenther Onkol Date: 2017-06-27 Impact factor: 3.621
Authors: Jianqing Lin; Robert B Den; Jacob Greenspan; Timothy N Showalter; Jean H Hoffman-Censits; Costas D Lallas; Edouard J Trabulsi; Leonard G Gomella; Mark D Hurwitz; Benjamin Leiby; Adam P Dicker; W Kevin Kelly Journal: Int J Radiat Oncol Biol Phys Date: 2020-02-03 Impact factor: 7.038
Authors: A-C Müller; J Lütjens; M Alber; F Eckert; M Bamberg; D Schilling; C Belka; U Ganswindt Journal: Strahlenther Onkol Date: 2012-10-11 Impact factor: 3.621
Authors: Anuja Jhingran; Lois M Ramondetta; Diane C Bodurka; Brian M Slomovitz; Jubilee Brown; Lawrence B Levy; Michael E Garcia; Patricia J Eifel; Karen H Lu; Thomas W Burke Journal: Gynecol Oncol Date: 2013-02-04 Impact factor: 5.482
Authors: F Alongi; B De Bari; P Franco; P Ciammella; T Chekrine; L Livi; B A Jereczek-Fossa; A R Filippi Journal: Radiol Med Date: 2013-01-28 Impact factor: 3.469